ID   LR-BT474
AC   CVCL_A2GH
DR   cancercelllines; CVCL_A2GH
DR   Wikidata; Q105509947
RX   PubMed=32942617;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:49603; Lapatinib (Tykerb; Tyverb).
CC   Sequence variation: Gene fusion; HGNC; 24618; AHCTF1 + HGNC; 736; NAAA; Name(s)=AHCTF1-NAAA (from parent cell line).
CC   Sequence variation: Gene fusion; HGNC; 7609; MYO9B + HGNC; 9764; RAB22A; Name(s)=RAB22A-MYO9B (from parent cell line).
CC   Sequence variation: Gene fusion; HGNC; 16173; DOK5 + HGNC; 17579; STARD3; Name(s)=STARD3-DOK5 (from parent cell line).
CC   Sequence variation: Gene fusion; HGNC; 16651; MRPL45 + HGNC; 16181; TRPC4AP; Name(s)=TRPC4AP-MRPL45 (from parent cell line).
CC   Sequence variation: Gene fusion; HGNC; 13178; IKZF3 + HGNC; 12649; VAPB; Name(s)=VAPB-IKZF3 (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ser3094Ter (c.9281C>A); ClinVar=VCV000188440; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11621; HNF1A; Simple; p.Gln495Ter (c.1483C>T); ClinVar=VCV000586785; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 6871; MAPK1; Simple; p.His61Gln (c.183C>G); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Lys111Asn (c.333G>C); ClinVar=VCV000376483; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu285Lys (c.853G>A); ClinVar=VCV000420133; Zygosity=Homozygous (from parent cell line).
CC   Omics: Transcriptome analysis by microarray.
CC   Derived from site: In situ; Breast; UBERON=UBERON_0000310.
DI   NCIt; C4194; Invasive breast carcinoma of no special type
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0179 ! BT-474
SX   Female
AG   60Y
CA   Cancer cell line
DT   Created: 12-01-21; Last updated: 05-10-23; Version: 5
//
RX   PubMed=32942617; DOI=10.3390/cancers12092630;
RA   Lee H.J., Shin S., Kang J., Han K.-C., Kim Y.H., Bae J.-W., Park K.H.;
RT   "HSP90 inhibitor, 17-DMAG, alone and in combination with lapatinib
RT   attenuates acquired lapatinib-resistance in ER-positive,
RT   HER2-overexpressing breast cancer cell line.";
RL   Cancers (Basel) 12:2630.1-2630.16(2020).
//